Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients at Least 70 Years of Age Compared with Patients Younger than 70 Years

Tomasz (Tom) Beer, William Berry, Emily M. Wersinger, Lisa B. Bland

    Research output: Contribution to journalArticle

    46 Citations (Scopus)

    Abstract

    We sought to determine whether age was significantly associated with efficacy and toxicity of weekly docetaxel in patients with metastatic androgen-independent prostate cancer (AIPC). Individual patient data were pooled from 2 phase II clinical trials of weekly docetaxel 36 mg/m2 for 6 of every 8 weeks in men with metastatic AIPC. Baseline characteristics and outcome measures of men ≥ 70 years of age (n = 52) were compared with patients <70 of age (n = 34) using Pearson χ2 test for categoric variables, Mann-Whitney U test for continuous variables, and log-rank test of Kaplan-Meier estimates for time-dependent variable. Multivariate analysis was used to adjust for any imbalances in baseline characteristics. At baseline, older patients had a lower hemoglobin level (P = 0.05) and a higher serum prostate-specific antigen (PSA; P = 0.04). The PSA response rate was 47% (95% Cl, 33%-62%) in older patients and 40% (95% Cl, 23%-59%) in younger patients (P = 0.75). Similarly, measurable disease response rate (P = 0.43), time to progression (P = 0.28), and survival (P = 0.52) were not affected by age in both univariate and multivariate analyses. There was also no difference in overall hematologic and nonhematologic toxicity ≥ grade 2. This comparison of pooled individual patient data from 2 phase II studies of weekly docetaxel in AIPC did not reveal significant differences in efficacy or toxicity in men aged ≥ 70 years compared with younger patients. These findings are consistent with the hypothesis that docetaxel chemotherapy in patients with AIPC is equally well tolerated and effective across a wide range of ages.

    Original languageEnglish (US)
    Pages (from-to)167-172
    Number of pages6
    JournalClinical Prostate Cancer
    Volume2
    Issue number3
    StatePublished - Dec 2003

    Fingerprint

    docetaxel
    Prostatic Neoplasms
    Androgens
    Multivariate Analysis
    Phase II Clinical Trials
    Kaplan-Meier Estimate
    Prostate-Specific Antigen
    Nonparametric Statistics

    Keywords

    • Age
    • Androgen-independent prostate cancer
    • Performance status
    • Prostate-specific antigen

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Cite this

    Weekly Docetaxel in Elderly Patients with Prostate Cancer : Efficacy and Toxicity in Patients at Least 70 Years of Age Compared with Patients Younger than 70 Years. / Beer, Tomasz (Tom); Berry, William; Wersinger, Emily M.; Bland, Lisa B.

    In: Clinical Prostate Cancer, Vol. 2, No. 3, 12.2003, p. 167-172.

    Research output: Contribution to journalArticle

    @article{a0a84085b5554c7284b627d18b12fb98,
    title = "Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients at Least 70 Years of Age Compared with Patients Younger than 70 Years",
    abstract = "We sought to determine whether age was significantly associated with efficacy and toxicity of weekly docetaxel in patients with metastatic androgen-independent prostate cancer (AIPC). Individual patient data were pooled from 2 phase II clinical trials of weekly docetaxel 36 mg/m2 for 6 of every 8 weeks in men with metastatic AIPC. Baseline characteristics and outcome measures of men ≥ 70 years of age (n = 52) were compared with patients <70 of age (n = 34) using Pearson χ2 test for categoric variables, Mann-Whitney U test for continuous variables, and log-rank test of Kaplan-Meier estimates for time-dependent variable. Multivariate analysis was used to adjust for any imbalances in baseline characteristics. At baseline, older patients had a lower hemoglobin level (P = 0.05) and a higher serum prostate-specific antigen (PSA; P = 0.04). The PSA response rate was 47{\%} (95{\%} Cl, 33{\%}-62{\%}) in older patients and 40{\%} (95{\%} Cl, 23{\%}-59{\%}) in younger patients (P = 0.75). Similarly, measurable disease response rate (P = 0.43), time to progression (P = 0.28), and survival (P = 0.52) were not affected by age in both univariate and multivariate analyses. There was also no difference in overall hematologic and nonhematologic toxicity ≥ grade 2. This comparison of pooled individual patient data from 2 phase II studies of weekly docetaxel in AIPC did not reveal significant differences in efficacy or toxicity in men aged ≥ 70 years compared with younger patients. These findings are consistent with the hypothesis that docetaxel chemotherapy in patients with AIPC is equally well tolerated and effective across a wide range of ages.",
    keywords = "Age, Androgen-independent prostate cancer, Performance status, Prostate-specific antigen",
    author = "Beer, {Tomasz (Tom)} and William Berry and Wersinger, {Emily M.} and Bland, {Lisa B.}",
    year = "2003",
    month = "12",
    language = "English (US)",
    volume = "2",
    pages = "167--172",
    journal = "Clinical Genitourinary Cancer",
    issn = "1558-7673",
    publisher = "Elsevier",
    number = "3",

    }

    TY - JOUR

    T1 - Weekly Docetaxel in Elderly Patients with Prostate Cancer

    T2 - Efficacy and Toxicity in Patients at Least 70 Years of Age Compared with Patients Younger than 70 Years

    AU - Beer, Tomasz (Tom)

    AU - Berry, William

    AU - Wersinger, Emily M.

    AU - Bland, Lisa B.

    PY - 2003/12

    Y1 - 2003/12

    N2 - We sought to determine whether age was significantly associated with efficacy and toxicity of weekly docetaxel in patients with metastatic androgen-independent prostate cancer (AIPC). Individual patient data were pooled from 2 phase II clinical trials of weekly docetaxel 36 mg/m2 for 6 of every 8 weeks in men with metastatic AIPC. Baseline characteristics and outcome measures of men ≥ 70 years of age (n = 52) were compared with patients <70 of age (n = 34) using Pearson χ2 test for categoric variables, Mann-Whitney U test for continuous variables, and log-rank test of Kaplan-Meier estimates for time-dependent variable. Multivariate analysis was used to adjust for any imbalances in baseline characteristics. At baseline, older patients had a lower hemoglobin level (P = 0.05) and a higher serum prostate-specific antigen (PSA; P = 0.04). The PSA response rate was 47% (95% Cl, 33%-62%) in older patients and 40% (95% Cl, 23%-59%) in younger patients (P = 0.75). Similarly, measurable disease response rate (P = 0.43), time to progression (P = 0.28), and survival (P = 0.52) were not affected by age in both univariate and multivariate analyses. There was also no difference in overall hematologic and nonhematologic toxicity ≥ grade 2. This comparison of pooled individual patient data from 2 phase II studies of weekly docetaxel in AIPC did not reveal significant differences in efficacy or toxicity in men aged ≥ 70 years compared with younger patients. These findings are consistent with the hypothesis that docetaxel chemotherapy in patients with AIPC is equally well tolerated and effective across a wide range of ages.

    AB - We sought to determine whether age was significantly associated with efficacy and toxicity of weekly docetaxel in patients with metastatic androgen-independent prostate cancer (AIPC). Individual patient data were pooled from 2 phase II clinical trials of weekly docetaxel 36 mg/m2 for 6 of every 8 weeks in men with metastatic AIPC. Baseline characteristics and outcome measures of men ≥ 70 years of age (n = 52) were compared with patients <70 of age (n = 34) using Pearson χ2 test for categoric variables, Mann-Whitney U test for continuous variables, and log-rank test of Kaplan-Meier estimates for time-dependent variable. Multivariate analysis was used to adjust for any imbalances in baseline characteristics. At baseline, older patients had a lower hemoglobin level (P = 0.05) and a higher serum prostate-specific antigen (PSA; P = 0.04). The PSA response rate was 47% (95% Cl, 33%-62%) in older patients and 40% (95% Cl, 23%-59%) in younger patients (P = 0.75). Similarly, measurable disease response rate (P = 0.43), time to progression (P = 0.28), and survival (P = 0.52) were not affected by age in both univariate and multivariate analyses. There was also no difference in overall hematologic and nonhematologic toxicity ≥ grade 2. This comparison of pooled individual patient data from 2 phase II studies of weekly docetaxel in AIPC did not reveal significant differences in efficacy or toxicity in men aged ≥ 70 years compared with younger patients. These findings are consistent with the hypothesis that docetaxel chemotherapy in patients with AIPC is equally well tolerated and effective across a wide range of ages.

    KW - Age

    KW - Androgen-independent prostate cancer

    KW - Performance status

    KW - Prostate-specific antigen

    UR - http://www.scopus.com/inward/record.url?scp=0346334660&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0346334660&partnerID=8YFLogxK

    M3 - Article

    C2 - 15040860

    AN - SCOPUS:0346334660

    VL - 2

    SP - 167

    EP - 172

    JO - Clinical Genitourinary Cancer

    JF - Clinical Genitourinary Cancer

    SN - 1558-7673

    IS - 3

    ER -